SciBase

PreMD Inc. is dedicated to saving and improving people's lives with simple, painless and patient-friendly tests that can detect life-threatening illnesses at a. The company's tests do not require any patient preparation or dietary restrictions and can be performed at the point of care, in a laboratory setting and, in some cases, even at home. The company's cardiovascular risk assessment technology, PREVU* Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues. PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The company's cancer tests are in development.

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

NanoMagnetics Instruments has been founded in Oxford, UK in 1998. The company's aim was to produce Scanning Hall Probe Microscope (SHPM) for room temperature applications at the beginning. The quantitative and non-invasive magnetic imaging capabilities of hall probe with high resolution are needed for many applications in science and technology. These directed us to embody the company's first product, Room Temperature Scanning Hall Probe Microscope (RT-SHPM) for the market. The another requirement for basic researches in condensed matter physics was for low temperature magnetic imaging applications of hall probes like superconductivity, quantum hall effect, etc.. The company desgined Low Temperature Scanning Hall Probe Microscope (LT-SHPM). The company's design was so flexible and compatible with many cryostats, He3 systems, Dilution Refrigerator systems. This flexilibility enabled us to operate the company's LT-SHPM for milli-Kelvin applications for many hot Low Temperature physics problems. n Recently, Scanning Tunnelling Microscope (STM) and Self-sensing AFM techniques like Quartz Crystal Tuning Fork and Akiyama Sensors options were added both LT and RT SPMs.n In 2002, the company signed a record and produced known Smallest Hall Sensor in the world, 50 nm. It is still unprecedendent spatial resolution limit for the hall sensors with extreme magnetic field resolutions around a couple of mG/u221aHz range at room temperature conditions. The filed resolution is much better for LHe temperatures: 6nT /u221aHz.n However, basic researches and industry still requires higher spatial resolutions. Needs determines the inventions and improvements. At this point, the company have presented the company's new product Low Temperature Magnetic Force Microscope (LT-MFM) for high resolution magnetic imaging, in 2007. The company's MFM depends on fiber interferometer detection technique with alignment free cantilevers. All AFM modes are available for low temperature ranges between 300K and 300mK like, EFM, Scanning Spreading Resistance, etc.n Today, the company are their powerful SPM solution partner in nanoscience and technology with the company's broad product range all around the world. Use this power!

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Tomophase Corporation was founded with the mission of developing solutions for minimally invasive diagnostic (MID) imaging. The company is using light to guide new ways of diagnosing diseases and has conceived major ideas for an optical MID imaging system

Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. The company offers personalized solutions through its image-to-implant platinum services program as well as data-informed, standardized solutions. It was founded in 2004 and is based in Billerica, Massachusetts.